Cargando…
Humanized COVID‐19 decoy antibody effectively blocks viral entry and prevents SARS‐CoV‐2 infection
To circumvent the devastating pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, a humanized decoy antibody (ACE2‐Fc fusion protein) was designed to target the interaction between viral spike protein and its cellular receptor, angiotensin‐converting enzyme 2 (...
Autores principales: | Huang, Kuo‐Yen, Lin, Ming‐Shiu, Kuo, Ting‐Chun, Chen, Ci‐Ling, Lin, Chung‐Chih, Chou, Yu‐Chi, Chao, Tai‐Ling, Pang, Yu‐Hao, Kao, Han‐Chieh, Huang, Rih‐Sheng, Lin, Steven, Chang, Sui‐Yuan, Yang, Pan‐Chyr |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7799362/ https://www.ncbi.nlm.nih.gov/pubmed/33159417 http://dx.doi.org/10.15252/emmm.202012828 |
Ejemplares similares
-
Using host receptor as a decoy to treat COVID‐19: a solution for immune escape?
por: Huang, Kuo‐Yen, et al.
Publicado: (2022) -
Nanoparticle composite TPNT1 is effective against SARS-CoV-2 and influenza viruses
por: Chang, Sui-Yuan, et al.
Publicado: (2021) -
Small-molecule PIK-93 modulates the tumor microenvironment to improve immune checkpoint blockade response
por: Lin, Chia-Yi, et al.
Publicado: (2023) -
The CH24H metabolite, 24HC, blocks viral entry by disrupting intracellular cholesterol homeostasis
por: Yuan, Yueming, et al.
Publicado: (2023) -
Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2
por: Lee, Richard Kuan-Lin, et al.
Publicado: (2022)